Finder's Pick for
Vir Biotechnology is a biotechnology business based in the US. Vir Biotechnology stocks (VIR.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $26.65 – an increase of 7.89% over the previous week. Vir Biotechnology employs 444 staff and has a trailing 12-month revenue of around $2.3 billion.
|Latest market close||$26.65|
|52-week range||$18.21 - $58.00|
|50-day moving average||$23.19|
|200-day moving average||$32.30|
|Wall St. target price||$52.71|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$8.99|
Note: The dollar amounts in the table below are in Canadian dollars.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2022-06-21)||7.89%|
|1 month (2022-05-27)||-0.19%|
|3 months (2022-03-28)||25.77%|
|6 months (2021-12-28)||-32.33%|
|1 year (2021-06-28)||-43.14%|
|2 years (2020-06-26)||-31.37%|
|3 years (2019-06-24)||N/A|
|5 years (2017-06-24)||N/A|
Valuing Vir Biotechnology stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vir Biotechnology's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vir Biotechnology's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Vir Biotechnology shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Vir Biotechnology's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.6 billion.
The EBITDA is a measure of a Vir Biotechnology's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.3 billion|
|Operating margin TTM||70.59%|
|Gross profit TTM||$590.7 million|
|Return on assets TTM||51.02%|
|Return on equity TTM||91.71%|
|Market capitalisation||$3.3 billion|
TTM: trailing 12 months
We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.
Over the last 12 months, Vir Biotechnology's shares have ranged in value from as little as $18.21 up to $58. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vir Biotechnology's is -0.5804. This would suggest that Vir Biotechnology's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Vir Biotechnology has bucked the trend.
Vir Biotechnology, Inc. , a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd. ; and a collaborative research agreement with GlaxoSmithKline Biologicals SA.
Here are the best Canadian investment newsletters to help you boost your investment knowledge and grow your wealth.Read more…
Here are some investment ideas that could do well despite rising interest rates.Read more…
iGaming is now legal in Ontario. Find out which companies to keep an eye on with our list of 10 top online gaming stocks.Read more…
Steps to owning and managing ADN stock, with 24-hour and historical pricing before you buy.
Everything we know about the Mobilicom Limited IPO plus information on how to buy in.
Steps to owning and managing XLP stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing SCHH stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing IYK stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing VNQ stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing KIE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing XLF stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing PXE stock, with 24-hour and historical pricing before you buy.
Steps to owning and managing FCG stock, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.